Grants Search Results

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Funding from the St. Baldrick's Foundation has taken two very small programs at UIC and Rush Medical Centers, merged them and brought Stroger Medical Center into the fold to forge a single entity for purposes of participation in Children's Oncology Group clinical trials. This support of necessary personnel has significantly increased clinical trial participation for patients who otherwise might not have access to them.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The grant is named in honor of the Do It for Dominic Fund. This Hero Fund was created in memory of Dominic Cairo, who died from Non-Hodgkin Lymphoma at the age of 8. His family and friends continue to focus their efforts on raising funds and supporting St. Baldrick’s in the effort find cures for childhood cancers in the hopes that no child ever has to go through what Dominic had to endure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Based on progress to date, Dr. Aune was awarded new grants in 2017 and 2018 to fund additional years of this Scholar award. Survival from pediatric cancer approaches 80%, but long-term survivors have alarming rates of heart disease as adults. Dr. Aune's lab has developed models to study how pediatric cancer therapies affect the heart. This research aims to determine the potential for new chemotherapy agents to damage the heart. These strategies will lead to a better quality of life for children who survive cancer.

Based on progress to date, Dr. Green was awarded a new grant in 2016 to fund an additional year of this Fellow award. High-grade gliomas (HGG) are brain tumors that are usually fatal in children. Dr. Green's work has recently shown promising results using a new medicine called Selinexor in laboratory models of HGG. Dr. Green, the Luke’s Army Pediatric Cancer Research Fund St. Baldrick’s Fellow, believes Selinexor works by restoring the function of proteins that suppress the tumor and acts as the brakes in cancer cells. Dr. Green's team is testing Selinexor for safety in children with various brain and solid tumors, and to see if it can extend survival.

A portion of this grant is named for the Luke's Army Pediatric Cancer Research Fund. Luke Ungerer brought smiles and sunshine wherever he went with plenty to share with everyone. He battled a brain tumor with a positive spirit and inspired others with his courage in his short life. This fund was created to carry on Luke’s legacy of positivity with the hope that it will ripple across many lives for many years to come. Awarded at Boston Children's Hospital and transferred to University of Colorado.

While great advances have been made in childhood cancer treatment, all children do not benefit equally from these innovations. Previous research suggests that disadvantaged children are more likely to die from cancer because their families have difficulty complying with treatment guidelines. Enhancing childhood cancer families’ abilities to adhere to treatment protocols is of critical importance to ensure that all children benefit from innovations in care. Dr. Gage-Bouchard is examining the factors that shape families’ abilities to comply with treatment protocols – a critical first step in developing interventions to increase treatment adherence among children diagnosed with cancer.

This grant funds a medical student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

This grant funds a student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty.

Based on progress to date, Dr. Barbieri was awarded new grants in 2017 and 2018 to fund additional years of this Scholar award. More than half of the patients with high-risk neuroblastoma will relapse despite intensive multimodal therapy. Treatments for these patients are challenging given disease heterogeneity, drug resistance, and toxicity. Dr. Barbieri’s project aims to develop novel targeted therapies for children with high-risk neuroblastoma whose disease is unresponsive to conventional therapies. By better understanding the metabolic changes occurring during the development of neuroblastoma, we will improve the clinical efficacy of current differentiating therapies for this aggressive disease.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

Most children treated for cancer can now expect to be cured. However, in a significant majority, future fertility may be compromised by their disease or its treatment. Girls are particularly at risk to ovarian injury. These children are cured; however the girls will live the rest of their life in menopause and they will also sadly be unable to have a child of their own. Dr. Lukish's work aims to open the field of ovarian cryopreservation in children by providing an evidence base for future practice, with significant potential benefit to young girls with cancer.

Langerhans cell histiocytosis (LCH) is a very rare type of neoplasm of the blood that has not been well investigated. It has been traditionally excluded from the major cooperative research groups, and thus considered an orphan disease. However, LCH affects many children. This consortium uses a uniform treatment while investigating the biology of the disease to seek for better therapeutic targets. Awarded at Dana-Farber Cancer Institute and transferred to St. Jude Children's Research Hospital. Funds administered by St. Jude Children's Research Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: New Approaches to Neuroblastoma Therapy (NANT) Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital Los Angeles, Los Angeles, CA.